Interactive Investor
>>

Faron Pharmaceuticals Oy (LSE:FARN) Share Price

FARN

Faron Pharmaceuticals Oy

UK company

Right Arrow 1

Healthcare

Right Arrow 2

Biotechnology

 / 

- / -
-
- / -
-
-
-

Bid

-

Ask

-

Last Traded

-

Chg

-

-

XLON

-

Updated: -

Research

News & analysis

Regulatory news

Loading...

Times are shown in BST, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.

This stock can be held in:

 / 

- / -
-
- / -
-
-
-

Company Profile

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company developing novel treatments for medicalconditions. The company currently has a pipeline focusing on acute organ traumas,vascular damage and cancer immunotherapy.

LSE:FARN

FI4000153309

GBX

Loading...

Loading Comparison

Latest FARN News

FARN Regulatory News